ABSTRACT
Resveratrol (RSV), the primary polyphenol found in grapes, has been revealed to have anti-inflammatory properties by reducing the capacity of the peripheral blood mononuclear cells to produce pro-inflammatory cytokines, including IL-1ß, IL-6, IL-1ra and TNFα. Considering the close association between chronic inflammation and cancer development, RSV's immunomodulatory properties are one way by which the polyphenol may inhibit cancer initiation, proliferation, neovascularization, and migration. Resveratrol influences the generation of microtumor environment which is one of the key factors in cancer progress. In addition to immunomodulation, RSV inhibits cancer development by expressing anti-oxidant effects, causing cell cycle arrest, stimulating the function of certain enzymes, and activating cell signaling pathways. The end outcome is one of the various forms of cell death, including apoptosis, pyroptosis, necroptosis, and more, as it has been observed in vitro. RSV has been shown to act against cancer in practically every organ, while its effects on colon cancer have been documented more frequently. It is remarkable that longer-term clinical studies that may have established the potential for this natural substance to serve as a therapeutic adjuvant to traditional anti-cancer medications were not prompted by the encouraging outcomes seen with cancer cells treated with non-toxic doses of resveratrol. The current review aims to assess the recent findings about the immunological and anti-cancer characteristics of RSV, with a particular emphasis on cancers of the digestive tract, as a challenge for future clinical research that may contribute to the better prognosis of cancer.
Subject(s)
Digestive System Neoplasms , Resveratrol , Resveratrol/pharmacology , Resveratrol/therapeutic use , Humans , Digestive System Neoplasms/drug therapy , Digestive System Neoplasms/prevention & control , Animals , Immunomodulating Agents/pharmacology , Immunomodulating Agents/therapeutic use , Immunologic Factors/pharmacology , Immunologic Factors/therapeutic use , Antineoplastic Agents, Phytogenic/pharmacology , Antineoplastic Agents, Phytogenic/therapeutic use , Anticarcinogenic Agents/pharmacology , Anticarcinogenic Agents/therapeutic useABSTRACT
CAR T-cell therapy is a promising immunotherapy, providing successful results for cancer patients who are unresponsive to standard and traditional therapeutic approaches. However, there are limiting factors which create a hurdle in the therapy performing its role optimally. CAR T cells get exhausted, produce active antitumor responses, and might even produce toxic reactions. Specifically, in the case of solid tumors, chimeric antigen receptor T (CAR-T) cells fail to produce the desired outcomes. Then, the need to use supplementary agents such as immune system modifying immunomodulatory agents comes into play. A series of the literature was studied to evaluate the role of immunomodulators including a phytochemical, Food and Drug Administration (FDA)-approved targeted drugs, and ILs in support of their achievements in boosting the efficiency of CAR-T cell therapy. Some of the most promising out of them are reported in this article. It is expected that by using the right combinations of immunotherapy, immunomodulators, and traditional cancer treatments, the best possible cancer defying results may be produced in the future.
Subject(s)
Immunotherapy, Adoptive , Neoplasms , Receptors, Chimeric Antigen , Humans , Neoplasms/therapy , Neoplasms/immunology , Immunotherapy, Adoptive/methods , Receptors, Chimeric Antigen/immunology , Immunologic Factors/therapeutic use , Immunomodulating Agents/therapeutic use , Immunomodulating Agents/pharmacology , T-Lymphocytes/immunology , Immunotherapy/methodsABSTRACT
Inflammatory bowel disease (IBD) is a chronic, lifelong disorder characterized by inflammation of the gastrointestinal (GI) tract. The exact etiology of IBD remains incompletely understood due to its multifaceted nature, which includes genetic predisposition, environmental factors, and host immune response dysfunction. Currently, there is no cure for IBD. This review discusses the available treatment options and the challenges they present. Importantly, we examine emerging therapeutics, such as biologics and immunomodulators, that offer targeted treatment strategies for IBD. While many IBD patients do not respond adequately to most biologics, recent clinical trials combining biologics with small-molecule drugs (SMDs) have provided new insights into improving the IBD treatment landscape. Furthermore, numerous novel and specific therapeutic targets have been identified. The high cost of IBD drugs poses a significant barrier to treatment, but this challenge may be alleviated with the development of more affordable biosimilars. Additionally, emerging point-of-care protein biomarkers from serum and plasma are showing potential for enhancing the precision of IBD diagnosis and prognosis. Several natural products (NPs), including crude extracts, small molecules, and peptides, have demonstrated promising anti-inflammatory activity in high-throughput screening (HTS) systems and advanced artificial intelligence (AI)-assisted platforms, such as molecular docking and ADMET prediction. These platforms are advancing the search for alternative IBD therapies derived from natural sources, potentially leading to more affordable and safer treatment options with fewer side effects.
Subject(s)
Biological Products , Inflammatory Bowel Diseases , Humans , Inflammatory Bowel Diseases/drug therapy , Biological Products/therapeutic use , Anti-Inflammatory Agents/therapeutic use , Anti-Inflammatory Agents/pharmacology , Biomarkers , Animals , Immunomodulating Agents/therapeutic use , Immunomodulating Agents/chemistryABSTRACT
Coronavirus disease 2019 (COVID-19) was declared a global pandemic in March 2020, which precipitated urgent public health responses. The causative agent, SARS-CoV-2, spreads primarily via respiratory droplets, necessitating precautions to mitigate transmission risks. Biopharmaceutical industries and academic institutions worldwide swiftly redirected their research endeavors towards developing therapeutic interventions, focusing on monoclonal antibodies, antiviral agents, and immunomodulatory therapies. The evolving body of evidence surrounding these treatments has prompted successive updates and revisions from the FDA, delineating the evolving landscape of COVID-19 therapeutics. This review comprehensively examines each treatment modality within the context of their developmental trajectories and regulatory approvals throughout the pandemic. Furthermore, it elucidates their mechanisms of action and presents clinical data underpinning their utility in combating the COVID-19 crisis.
Subject(s)
Antiviral Agents , COVID-19 Drug Treatment , COVID-19 , Drug Development , SARS-CoV-2 , Humans , Antiviral Agents/pharmacology , Antiviral Agents/therapeutic use , SARS-CoV-2/drug effects , Drug Development/methods , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal/pharmacology , Immunomodulating Agents/pharmacology , Immunomodulating Agents/therapeutic use , Animals , PandemicsABSTRACT
BACKGROUND: There are only a few recognized drug targets for cerebral small vessel disease (CSVD). Though inflammation is increasingly implicated in the development of CSVD, it remains unclear whether immunomodulation could become a therapeutic target. Accordingly, the Mendelian randomization (MR) method was used to assess the genetically proxied impacts of IL6 receptor (IL6R) inhibitor, IL1ß inhibitor, Tumor necrosis factor (TNF) inhibitor and ß-tubulin inhibitor on CSVD through. METHODS: Single nucleotide polymorphisms (SNPs) near the IL6R, IL1ß, TNFRSF1A and ß-tubulin genes were identified as genetic proxies for immunomodulatory drugs. These SNPs exhibited significant associations with serum C-reactive protein (CRP) levels in a large European genome-wide association study. The causal effects of immunomodulatory drugs on CSVD manifestations and the mediation influence of 731 peripheral blood immune phenotypes linking these drugs to CSVD manifestations were examined using a two-sample two-step MR approach. RESULTS: A total of 9, 18, 4 and 1 SNP were identified to proxy the effects of IL1ß inhibitor, IL6R inhibitor, TNF inhibitor and ß-tubulin inhibitor, respectively. MR analysis showed a significant causal relationship between IL1ß inhibition and reduced volume of periventricular white matter hyperintensity (PWMH). IL6R inhibition was associated with a reduced risk of small vessel stroke, decreased axial diffusivity and mean diffusivity. Genetically proxied TNF inhibition may decrease the occurrence of cerebral microbleeds (CMBs) and severe enlarged perivascular spaces located at white matter (WM-EPVS). It could also protect WM integrity, as evidenced by the reduced volumes of PWMH and deep white matter hyperintensity (DWMH). Various peripheral blood immune phenotypes exhibited significant associations with immunomodulatory drugs. Notably, the median fluorescence intensity (MFI) of CD45 on CD8br cells partially mediated the effects of IL1ß inhibitor on PWMH volume. Indirect effects of TNF inhibition on PWMH and DWMH volume through the MFI of CD127 on CD28- CD8br cells were observed. The effects of TNF inhibition on the occurrence of any CMBs were partially mediated by the MFI of CD45 on natural killer T cells, and the effects of TNF inhibition on the occurrence of lobar CMBs were partially mediated by the MFI of HLA DR on CD33- HLA DR+ cells. Furthermore, the MFI of HLA DR on CD33- HLA DR+ cells partially mediated the effects of TNF inhibition on WM-EPVS. CONCLUSIONS: IL1ß inhibitor, IL6R inhibitor and TNF inhibitor were associated with lower burden of CSVD while the activation of certain immune cells such as Tregs and myeloid cells partially mediated their protective effects.
Subject(s)
Cerebral Small Vessel Diseases , Genome-Wide Association Study , Interleukin-1beta , Mendelian Randomization Analysis , Polymorphism, Single Nucleotide , Cerebral Small Vessel Diseases/genetics , Cerebral Small Vessel Diseases/drug therapy , Humans , Interleukin-1beta/genetics , Immunomodulating Agents/therapeutic use , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Tumor Necrosis Factor-alpha/genetics , Receptors, Interleukin-6/antagonists & inhibitors , Receptors, Interleukin-6/genetics , Tubulin/geneticsABSTRACT
Cytokine storm syndromes (CSS) include different entities such as macrophage activation syndrome, primary and secondary hemophagocytic lymphohistiocytosis (HLH), and multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19. An effective management strategy is critical in CSS. While biologics have become an essential part of CSS treatment, hematopoietic stem cell transplantation (HSCT) has changed the fate of primary HLH patients. This chapter will focus on the available alternative immunomodulatory therapies in CSS, which include corticosteroids, cyclosporine A, intravenous immunoglobulin, interleukin 18 binding protein, therapeutic plasmapheresis, HSCT, and mesenchymal stromal cell-based therapies.
Subject(s)
COVID-19 , Cytokine Release Syndrome , Humans , Cytokine Release Syndrome/immunology , Cytokine Release Syndrome/therapy , COVID-19/immunology , COVID-19/therapy , COVID-19/complications , Hematopoietic Stem Cell Transplantation , SARS-CoV-2/immunology , Lymphohistiocytosis, Hemophagocytic/therapy , Lymphohistiocytosis, Hemophagocytic/immunology , Plasmapheresis/methods , Immunomodulating Agents/therapeutic use , Immunoglobulins, Intravenous/therapeutic use , Mesenchymal Stem Cell Transplantation/methods , Cyclosporine/therapeutic use , Systemic Inflammatory Response Syndrome/immunology , Systemic Inflammatory Response Syndrome/therapyABSTRACT
Keloids are pathologic responses to cutaneous injury. Current treatments, such as topical and intralesional steroids and even surgical excision, have limited efficacy, creating a demand for improved therapies. Our study explores the functioning of dupilumab, an interleukin-4 and inter-leukin-13 signaling pathway inhibitor, in this context. We have reviewed the literature for using dupilumab to treat keloids, evaluating safety and efficacy and offering recommendations for its application. We searched PubMed and Google Scholar using "Dupilumab" and "Keloid" as keywords. To ensure relevance, we limited the search to English language publications of 2018-2023. Dupilumab exhibited efficacy in keloid treatment, with notable improvements in patients. One patient reported a 50% reduction in the fibrotic plaque and complete resolution of smaller keloids without adverse effects. Two other patients reported successful stabilization and reduction in keloids following dupilumab therapy; however, the 12-week treatment demonstrated no response or reduction in post-treatment size or height of keloidals, with disease progression observed in one patient. One report discouraged the use of dupilumab for keloids due to limited positive responses. Considering dupilumab as the last therapeutic option to treat keloids may benef patients resistant to standard therapies and/or those highly motivated to reduce keloids.
Subject(s)
Antibodies, Monoclonal, Humanized , Keloid , Keloid/drug therapy , Humans , Antibodies, Monoclonal, Humanized/therapeutic use , Antibodies, Monoclonal, Humanized/pharmacology , Treatment Outcome , Immunomodulating Agents/therapeutic use , Immunomodulating Agents/pharmacologyABSTRACT
Infectious diseases are a major threat to global health and cause millions of deaths every year, particularly in developing countries. The emergence of multidrug resistance challenges current antimicrobial treatments, inducing uncertainty in therapeutic protocols. New compounds are therefore necessary. A drug repurposing approach could play a critical role in developing new treatments used either alone or in combination with standard therapy regimens. Herein, we focused on cysteamine, an aminothiol endogenously synthesized by human cells during the degradation of coenzyme-A, which is a drug approved for the treatment of nephropathic cystinosis. Cysteamine influences many biological processes due to the presence of the highly reactive thiol group. This review provides an overview of cysteamine-mediated effects on different viruses, bacteria and parasites, with a particular focus on infections caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Mycobacterium tuberculosis, non-tuberculous mycobacteria (NTM), and Pseudomonas aeruginosa. Evidences for a potential use of cysteamine as a direct antimicrobial agent and/or a host-directed therapy, either alone or in combination with other antimicrobial drugs, are described.
Subject(s)
Anti-Infective Agents , Cysteamine , Humans , Cysteamine/pharmacology , Cysteamine/therapeutic use , Anti-Infective Agents/pharmacology , Anti-Infective Agents/therapeutic use , Animals , Communicable Diseases/drug therapy , Communicable Diseases/microbiology , Drug Repositioning , Immunomodulating Agents/pharmacology , Immunomodulating Agents/therapeutic use , COVID-19 , COVID-19 Drug Treatment , SARS-CoV-2/drug effectsABSTRACT
A randomized, double-blind, placebo-controlled clinical trial was conducted to investigate the efficacy of infliximab, abatacept, and cenicriviroc in treating patients hospitalized with COVID-19. The patient's clinical status was assessed daily on an 8-point ordinal scale. We evaluated the totality of evidence on the efficacy of the 3 immunomodulators by considering all possible changes in the clinical status of each patient over time. We demonstrated that infliximab accelerated improvement and reduced deterioration of clinical status when added to standard of care. There was also evidence for the benefit of abatacept. There was no evidence for the benefit of cenicriviroc.
Subject(s)
Abatacept , COVID-19 Drug Treatment , COVID-19 , Infliximab , SARS-CoV-2 , Humans , Abatacept/therapeutic use , Infliximab/therapeutic use , Double-Blind Method , Male , Middle Aged , Female , Treatment Outcome , Aged , Hospitalization , Adult , Immunomodulating Agents/therapeutic useABSTRACT
Inflammatory bowel disease (IBD) is entering a potentially new era of combined therapeutics. Triantafillidis et al provide an insightful review of the current state of combination therapy, with a focus on the use of a combined biologic and immunomodulator, as well as emerging data on the future potential of dual-biologic therapy (DBT). While current evidence for DBT is limited, encouraging safety profiles and ongoing trials suggest a brighter future for this approach. The importance of controlled trials should be stressed in establishing new treatment paradigms. Ongoing prospective randomized trials of DBT and perhaps future combinations of biologics and small molecule therapies will hopefully guide the next generation of IBD care.
Subject(s)
Biological Products , Drug Therapy, Combination , Inflammatory Bowel Diseases , Humans , Inflammatory Bowel Diseases/drug therapy , Inflammatory Bowel Diseases/therapy , Inflammatory Bowel Diseases/immunology , Drug Therapy, Combination/methods , Biological Products/therapeutic use , Biological Products/administration & dosage , Treatment Outcome , Immunomodulating Agents/therapeutic use , Randomized Controlled Trials as TopicABSTRACT
Autoimmunity, allergy, and transplant rejection are a collection of chronic diseases that are currently incurable, drastically decrease patient quality of life, and consume considerable health care resources. Underlying each of these diseases is a dysregulated immune system that results in the mounting of an inflammatory response against self or an innocuous antigen. As a consequence, afflicted patients are required to adhere to lifelong regimens of multiple immunomodulatory drugs to control disease and reclaim agency. Unfortunately, current immunomodulatory drugs are associated with a myriad of side effects and adverse events, such as increased risk of cancer and increased risk of serious infection, which negatively impacts patient adherence rates and quality of life. The field of immunoengineering is a new discipline that aims to harness endogenous biological pathways to thwart disease and minimize side effects using novel biomaterial-based strategies. We highlight and discuss polymeric micro/nanoparticles with inherent immunomodulatory properties that are currently under investigation in biomaterial-based therapies for treatment of autoimmunity, allergy, and transplant rejection.
Subject(s)
Autoimmunity , Graft Rejection , Hypersensitivity , Polymers , Humans , Graft Rejection/immunology , Graft Rejection/prevention & control , Polymers/chemistry , Autoimmunity/drug effects , Hypersensitivity/immunology , Hypersensitivity/therapy , Animals , Biocompatible Materials/chemistry , Nanoparticles/chemistry , Autoimmune Diseases/therapy , Autoimmune Diseases/immunology , Immunomodulating Agents/therapeutic use , Immunologic Factors/therapeutic useABSTRACT
In the postantibiotic era, the pathogenicity and resistance of pathogens have increased, leading to an increase in intestinal inflammatory disease. Bacterial infections remain the leading cause of animal mortality. With increasing resistance to antibiotics, there has been a significant decrease in resistance to both inflammation and disease in animals, thus decreasing production efficiency and increasing production costs. These side effects have serious consequences and have detracted from the development of China's pig industry. Microcin C7 (McC7) demonstrates potent antibacterial activity against a broad spectrum of pathogens, stable physicochemical properties, and low toxicity, reducing the likelihood of resistance development. Thus, McC7 has received increasing attention as a potential clinical antibacterial and immunomodulatory agent. McC7 has the potential to serve as a new generation of antibiotic substitutes; however, its commercial applications in the livestock and poultry industry have been limited. In this review, we summarize and discuss the biosynthesis, biochemical properties, structural characteristics, mechanism of action, and immune strategies of McC7. We also describe the ability of McC7 to improve intestinal health. Our aim in this study was to provide a theoretical basis for the application of McC7 as a new feed additive or new veterinary drug in the livestock and poultry breeding industry, thus providing a new strategy for alleviating resistance through feed and mitigating drug resistance. Furthermore, this review provides insight into the new functions and anti-infection mechanisms of bacteriocin peptides and proposes crucial ideas for the research, product development, and application of bacteriocin peptides in different fields, such as the food and medical industries.
Subject(s)
Anti-Bacterial Agents , Bacteriocins , Bacteriocins/pharmacology , Bacteriocins/chemistry , Bacteriocins/therapeutic use , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/therapeutic use , Animals , Immunomodulating Agents/pharmacology , Immunomodulating Agents/chemistry , Immunomodulating Agents/therapeutic use , Swine , HumansABSTRACT
There are limited data on the optimal choice of anticoagulation in multiple myeloma (MM) patients receiving immunomodulatory drugs (IMiDs). We conducted a propensity score-matched cohort study using the TriNetX database to compare the efficacy and safety of factor Xa inhibitors and warfarin in this patient population. Compared to warfarin, factor Xa inhibitors had a similar risk of deep vein thrombosis (hazard ratio [HR]: 1.11 [95% CI: 0.50-2.46]) or pulmonary embolism (HR: 1.08 [95% CI: 0.59-2.00]). There were no differences in the risk of gastrointestinal or intracranial bleeding. Factor Xa inhibitor-treated patients had lower all-cause mortality (HR: 0.56 [95% CI: 0.36-0.86]) compared with warfarin. These data suggest that factor Xa inhibitors had similar safety and efficacy compared with warfarin for MM patients on IMiDs.
Subject(s)
Anticoagulants , Factor Xa Inhibitors , Multiple Myeloma , Warfarin , Humans , Warfarin/therapeutic use , Warfarin/adverse effects , Multiple Myeloma/drug therapy , Multiple Myeloma/complications , Multiple Myeloma/mortality , Factor Xa Inhibitors/therapeutic use , Factor Xa Inhibitors/adverse effects , Female , Male , Aged , Middle Aged , Anticoagulants/therapeutic use , Anticoagulants/adverse effects , Venous Thrombosis/prevention & control , Venous Thrombosis/etiology , Immunomodulating Agents/therapeutic use , Immunomodulating Agents/adverse effects , Aged, 80 and over , Pulmonary Embolism/prevention & control , Pulmonary Embolism/etiologyABSTRACT
Background: Immunomodulatory drugs and immunotherapies are being evaluated in clinical trials for the treatment of neuroinflammation, as the latter is an essential mechanism for the development and progression of Parkinson's disease. Objective: The objective of the study is to review recent evidence on the evaluation of immunomodulators in randomized controlled clinical trials measuring improvement of motor symptoms. Methods: A meta-analysis of Movement Disorder Society-Unified Parkinson's disease Rating Scale (MDS-UPDRS III) scores extracted from seven articles selected after an online search of PubMed, Cochrane Library, and Clarivate's Web of Science for randomized controlled clinical trials published between 2000 and July 2023 was performed. The selected articles reported clinical trials evaluating the effects of specific immunomodulators or treatments with known effects on the immune system and inflammation. MDS-UPDRS III scores were reported in these studies, and the results of the placebo groups were compared with those of the treatment groups. Results: A total of 590 patients treated with immunomodulators and 622 patients treated with placebo were included. A test for heterogeneity yielded an I2 value > 50%. The mean standard difference for change in MDS-UPDR III score was -0.46 (CI [95%] = -0.90 - -0.02, p < 0.01). No significant differences were found in the change in mean MDS-UPDR III score between the treatment and placebo groups; however, two studies showed a trend toward separation from the mean. Conclusion: The immunomodulatory treatments included in this study showed no efficacy in improving motor symptoms in Parkinson's disease patients. Further clinical trials with larger patient populations are needed.
Subject(s)
Immunomodulating Agents , Parkinson Disease , Randomized Controlled Trials as Topic , Parkinson Disease/drug therapy , Parkinson Disease/therapy , Humans , Immunomodulating Agents/administration & dosage , Immunomodulating Agents/therapeutic use , Immunomodulating Agents/pharmacology , Immunomodulation , Immunologic Factors/therapeutic use , Immunologic Factors/administration & dosage , Immunotherapy/methodsABSTRACT
INTRODUCTION: The treatment of multiple myeloma (MM) is evolving rapidly. Quadruplet regimens incorporating proteasome inhibitors, immunomodulatory drugs (IMiDs), and CD38 monoclonal antibodies have emerged as standard-of-care options for newly diagnosed MM, and numerous novel therapies have been approved for relapsed/refractory MM. However, there remains a need for novel options in multiple settings, including refractoriness to frontline standards of care. AREAS COVERED: Targeting degradation of IKZF1 and IKZF3 - Ikaros and Aiolos - through modulation of cereblon, an E3 ligase substrate recruiter/receptor, is a key mechanism of action of the IMiDs and the CELMoD agents. Two CELMoD agents, iberdomide and mezigdomide, have demonstrated substantial preclinical and clinical activity in MM and have entered phase 3 investigation. Using a literature search methodology comprising searches of PubMed (unlimited time-frame) and international hematology/oncology conference abstracts (2019-2023), this paper reviews the importance of Ikaros and Aiolos in MM, the mechanism of action of the IMiDs and CELMoD agents and their relative potency for targeting Ikaros and Aiolos, and preclinical and clinical data on iberdomide and mezigdomide. EXPERT OPINION: Emerging data suggest that iberdomide and mezigdomide have promising activity, including in IMiD-resistant settings and, pending phase 3 findings, may provide additional treatment options for patients with MM.
Subject(s)
Ikaros Transcription Factor , Multiple Myeloma , Thalidomide , Humans , Multiple Myeloma/drug therapy , Multiple Myeloma/metabolism , Ikaros Transcription Factor/metabolism , Thalidomide/therapeutic use , Thalidomide/analogs & derivatives , Thalidomide/pharmacology , Signaling Lymphocytic Activation Molecule Family/metabolism , Signaling Lymphocytic Activation Molecule Family/antagonists & inhibitors , Ubiquitin-Protein Ligases/metabolism , Antineoplastic Agents/therapeutic use , Antineoplastic Agents/pharmacology , Proteolysis/drug effects , Molecular Targeted Therapy , Immunomodulating Agents/therapeutic use , Immunomodulating Agents/pharmacology , Clinical Trials as Topic , Animals , Piperidones , Morpholines , Receptors, Interleukin-17 , Adaptor Proteins, Signal Transducing , PhthalimidesABSTRACT
Recurrent spontaneous abortion refers to the occurrence of two or more spontaneous abortions before or during the early stages of pregnancy. The immune system plays a crucial role in the maintenance of pregnancy and embryo implantation. Various immune cells, cytokines, and immune regulatory pathways are involved in the complex immune balance required for a stable pregnancy. Studies suggest that immune abnormalities may be associated with some recurrent spontaneous abortion cases, particularly those involving the dysregulation of immune cell function, autoimmune responses, and placental immunity. In terms of treatment, interventions targeting immune mechanisms are crucial. Various therapeutic approaches, including immunomodulatory drugs, immunoadsorption therapies, and immunocellular therapies, are continually being researched and developed. These approaches aim to restore the immune balance, enhance the success rate of pregnancies, and provide more effective treatment options for patients with recurrent spontaneous abortion.
Subject(s)
Abortion, Habitual , Humans , Abortion, Habitual/immunology , Abortion, Habitual/therapy , Female , Pregnancy , Animals , Immunomodulating Agents/therapeutic use , Placenta/immunologyABSTRACT
INTRODUCTION: Current treatment guidelines for cutaneous T cell lymphoma (CTCL) advocate a stage-driven approach, considering clinical presentation, symptom burden, and patient comorbidities. Therapy selection hinges on factors like disease subtype, severity, and treatment availability. The primary goal is to enhance the quality of life by mitigating symptoms, as achieving lasting complete remission is infrequent. AREAS COVERED: Over the past decade (2013-2023), the therapeutic landscape of CTCL has experienced substantial transformation with the introduction of innovative therapies. This review explores the main pivotal developments in traditional treatment schedules and recently introduced drugs, aiming to offer clinicians and researchers a thorough perspective on the decade's progress in the field. EXPERT OPINION: Despite the progress made in CTCL therapeutics, ranging from topical chemotherapeutics to immunomodulatory agents, several unmet needs persist. Firstly, there is a pressing need for the incorporation of readily available predictors for treatment response, encompassing clinical, pathological, and molecular features. Secondly, a more profound comprehension of the tumor microenvironment is imperative to optimize the landscape of targetable molecules. Lastly, the undertaking of studies on combination regimens should be encouraged as it enhances therapy efficacies by synergistically combining agents with diverse modes of action.
Subject(s)
Antineoplastic Agents , Lymphoma, T-Cell, Cutaneous , Quality of Life , Skin Neoplasms , Tumor Microenvironment , Humans , Lymphoma, T-Cell, Cutaneous/drug therapy , Lymphoma, T-Cell, Cutaneous/pathology , Skin Neoplasms/drug therapy , Skin Neoplasms/pathology , Antineoplastic Agents/therapeutic use , Tumor Microenvironment/drug effects , Animals , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Neoplasm Staging , Practice Guidelines as Topic , Immunomodulating Agents/therapeutic useABSTRACT
OBJECTIVE: Poor adherence to oral chemotherapy adversely impacts clinical outcomes and escalates overall healthcare costs. Despite barriers to medication adherence, a significant gap remains in assessing adherence to oral chemotherapy among multiple myeloma (MM) patients with lower socioeconomic status. Hence, our study aims to evaluate immunomodulator adherence in MM patients at a county hospital, primarily serving underrepresented and indigent individuals with low socioeconomic status across the greater Houston area. METHODS: Inclusion criteria composed of patients diagnosed with MM, aged at least 18 years, and treated with lenalidomide or pomalidomide-two widely used immunomodulators-for a minimum of 2 months or having two or more records of dispensation between May 2019 and May 2021. Adherence was gauged using an adjusted version of the medication possession ratio (MPR). RESULTS: Sixty-two patients were enrolled, yielding a mean MPR value of 88% (SD, ± 18.9). Of these, 43 patients (69.3%) demonstrated adherence with an MPR of ≥ 0.90. A significant difference was found in treatment duration between the adherent (mean 8.8 months; SD, ± 7.2) and non-adherent (mean 13.4 months; SD, ± 7.9) groups (p = 0.027). Notably, race/ethnicity demonstrated a significant difference (p = 0.048), driven by disparities in African American and Hispanic representation across adherence levels. CONCLUSION: In summary, our findings highlight race and treatment duration to be predictors of immunomodulator adherence among MM patients with lower socioeconomic status. Further research is imperative to devise and test innovative interventions aimed at enhancing medication adherence, thereby contributing to improved survival and healthcare quality in this population.
Subject(s)
Lenalidomide , Medication Adherence , Multiple Myeloma , Social Class , Thalidomide , Humans , Multiple Myeloma/drug therapy , Male , Retrospective Studies , Medication Adherence/statistics & numerical data , Female , Middle Aged , Aged , Thalidomide/therapeutic use , Thalidomide/analogs & derivatives , Thalidomide/administration & dosage , Lenalidomide/administration & dosage , Lenalidomide/therapeutic use , Immunologic Factors/therapeutic use , Immunologic Factors/administration & dosage , Immunomodulating Agents/therapeutic use , Immunomodulating Agents/administration & dosage , Immunomodulating Agents/pharmacology , Texas , Aged, 80 and over , AdultABSTRACT
BACKGROUND: Paediatric-onset and elderly-onset inflammatory bowel disease (IBD) present unique treatment challenges. AIMS: We investigated treatment patterns following a first and second course of systemic steroids in paediatric- and elderly-onset IBD and compared them to adult-onset IBD. METHODS: All patients diagnosed with Crohn's disease (CD) or ulcerative colitis (UC) between 2000 and 2018 were identified through the Danish healthcare registries. Patients were divided into groups based on their age at diagnosis. Kaplan-Meier plots were prepared for medications and surgeries after diagnosis and after the first and second courses of systemic steroids. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated using multivariate Cox regression analysis for steroid-sparing medications. RESULTS: 1851 CD (13%) and 1687 (6%) UC patients were paediatric-onset, while 2952 (20%) CD and 5812 (23%) UC patients were elderly-onset. Paediatric-onset more frequently received immunomodulators [CD: HR: 1.64, CI: 1.52-1.77, UC: HR: 2.29, CI: 2.02-2.61] and biologics [CD: HR: 1.43, CI: 1.25-1.65, UC: HR: 1.27, CI: 0.99-1.64], while elderly-onset less frequently received immunomodulators [CD: HR: 0.39, CI: 0.35-0.44, UC: HR: 0.58, CI: 0.50-0.67] and biologics [CD: HR: 0.19, CI: 0.14-0.25, UC: HR: 0.36, CI: 0.27-0.48] compared to adult-onset age groups. After two courses of systemic steroids, elderly-onset still received less steroid-sparing medications. High frailty was associated with lower usage of medications for elderly-onset. CONCLUSION: There are significant differences in the use of steroid-sparing medication between age of onset, even after two courses with systemic steroids. High frailty could account for some of these differences in elderly-onset IBD.
Subject(s)
Colitis, Ulcerative , Crohn Disease , Humans , Denmark , Male , Female , Adolescent , Adult , Aged , Child , Middle Aged , Crohn Disease/drug therapy , Young Adult , Colitis, Ulcerative/drug therapy , Age Factors , Cohort Studies , Age of Onset , Registries , Steroids/therapeutic use , Inflammatory Bowel Diseases/drug therapy , Immunomodulating Agents/therapeutic use , Child, Preschool , Treatment OutcomeABSTRACT
Immunomodulators can stimulate, suppress, or regulate one or many aspects of the immune response. Use of a variety of immunostimulants, immunosuppressors, and anti-inflammatory drugs are described in horses, but the evidence supporting their efficacy is variable. Corticosteroids and nonsteroidal anti-inflammatory drugs are the best characterized immunomodulators in horses, but further study is needed to fully define their ideal dosing protocols and indications and to characterize the efficacy of other immunomodulators in equine medicine.